TY - JOUR
T1 - Development and reversibility of aluminum-induced bone lesion in the rat
AU - Ott, Susan M.
AU - Feist, Elmer
AU - Andress, Dennis L.
AU - Liu, Chung C.
AU - Sherrard, Donald J.
AU - Alfrey, Allen C.
AU - Slatopolsky, Eduardo
AU - Howard, Guy A.
PY - 1987/1
Y1 - 1987/1
N2 - We studied the effect of aluminum injections on bones of rats after intervals of 3, 6, and 9 weeks. To study reversibility, we allowed one group to recover for 3 weeks. Both weanling and adult rats were examined to determine the influence of age. The calcium, phosphate, creatinine, and parathyroid hormone levels were similar in aluminum-treated rats and controls. Aluminum could be seen by histochemical stain after 6 weeks, but at that time the bone was otherwise normal. By 9 weeks the bone formation (as measured by tetracycline labeling) in aluminum-treated rats was severely decreased on trabecular and endosteal surfaces. The periosteal surfaces showed normal formation. After 3 weeks of recovery, the bone formation rate in the young aluminum-treated rats was similar to that in the controls, although the serum and bone aluminum values had not significantly decreased. A higher percentage of aluminum was seen in the cement lines. In the adult rats, the bones had more stainable aluminum, and increased osteoid was noted along trabecular and periosteal surfaces. The doses of aluminum used in these rats greatly exceeded those that cause toxiclty in humans; thus these findings may not directly apply to clinical practice. We conclude that aluminum administration can lead to decreased rates of bone formation in the rat, despite normal calcium level and renal function, and without decreased parathyroid hormone levels. The peritoneal route of administration could also have contributed to bone lesions by causing peritonitis, malabsorption, or both. Adult rats showed signs of early osteomalacia. Aluminum accumulates in the bone before the bone formation rate decreases. The abnormalities are not seen on the periosteal surfaces, suggesting that local factors may play a role in aluminum toxicity. The lesion is reversible when aluminum loading ceases.
AB - We studied the effect of aluminum injections on bones of rats after intervals of 3, 6, and 9 weeks. To study reversibility, we allowed one group to recover for 3 weeks. Both weanling and adult rats were examined to determine the influence of age. The calcium, phosphate, creatinine, and parathyroid hormone levels were similar in aluminum-treated rats and controls. Aluminum could be seen by histochemical stain after 6 weeks, but at that time the bone was otherwise normal. By 9 weeks the bone formation (as measured by tetracycline labeling) in aluminum-treated rats was severely decreased on trabecular and endosteal surfaces. The periosteal surfaces showed normal formation. After 3 weeks of recovery, the bone formation rate in the young aluminum-treated rats was similar to that in the controls, although the serum and bone aluminum values had not significantly decreased. A higher percentage of aluminum was seen in the cement lines. In the adult rats, the bones had more stainable aluminum, and increased osteoid was noted along trabecular and periosteal surfaces. The doses of aluminum used in these rats greatly exceeded those that cause toxiclty in humans; thus these findings may not directly apply to clinical practice. We conclude that aluminum administration can lead to decreased rates of bone formation in the rat, despite normal calcium level and renal function, and without decreased parathyroid hormone levels. The peritoneal route of administration could also have contributed to bone lesions by causing peritonitis, malabsorption, or both. Adult rats showed signs of early osteomalacia. Aluminum accumulates in the bone before the bone formation rate decreases. The abnormalities are not seen on the periosteal surfaces, suggesting that local factors may play a role in aluminum toxicity. The lesion is reversible when aluminum loading ceases.
UR - http://www.scopus.com/inward/record.url?scp=45949131493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45949131493&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:45949131493
VL - 109
SP - 34
EP - 39
JO - Translational Research
JF - Translational Research
SN - 1931-5244
IS - 1
ER -